GDF15作为T3/T4cN0M0口腔鳞癌患者TPF诱导化疗预测性生物标志物的探讨

中国口腔颌面外科杂志 ›› 2016, Vol. 14 ›› Issue (2): 117-122.

GDF15作为T3/T4cN0M0口腔鳞癌患者TPF诱导化疗预测性生物标志物的探讨

唐晓¹, 孙文文¹, 朱东旺¹, 马捷¹, 马海龙¹, 刘莹¹, 谈亦然¹, 涂瑶瑶¹, 王丽珍², 李江², 钟来平¹, 张陈平¹, 张志愿¹

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科;
2.口腔病理科;上海市口腔医学重点实验室,上海 200011

收稿日期:2015-06-17 出版日期:2016-03-20 发布日期:2016-04-06
通讯作者: 钟来平,Tel：021-23271699-5160,E-mail:zhonglaiping@163.com
作者简介:唐晓（1990-）,男,在读硕士研究生,E-mail:tangxiao_900901@163.com
基金资助:
国家自然科学基金（81472519）; 上海市科学技术委员会基金（13QH1401700）; 上海市人才发展资金（201447）

GDF15 can be used as a potential predictive biomarker for TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

TANG Xiao¹, SUN Wen-wen¹, ZHU Dong-wang¹, MA Jie¹, MA Hai-long¹, LIU Ying¹, TAN Yi-ran¹, TU Yao-yao¹, WANG Li-zhen², LI Jiang², ZHONG Lai-ping¹, ZHANG Chen-ping¹, ZHNAG Zhi-yuan¹

1.Department of Oromaxillofacial Head and Neck Oncology, 2.Department of Oral Pathology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2015-06-17 Online:2016-03-20 Published:2016-04-06

摘要/Abstract

摘要： 目的:探讨GDF15表达能否作为局部晚期口腔鳞癌的预后生物标志物,以及预测TPF（多西他赛、顺铂和5-氟尿嘧啶）诱导化疗疗效的生物标志物。方法:以256例局部晚期口腔鳞癌的前瞻性临床试验患者为研究对象,采用免疫组织化学方法,检测患者活检样本中GDF15的表达情况,分析其与TPF诱导化疗的预后关系。采用SPSS18.0软件包对数据进行统计学分析。结果:在具有活检样本的230例口腔鳞癌患者中,低表达GDF15的患者68例,高表达GDF15的患者162例。低表达GDF15的患者具有较好的总生存率（P=0.046）、无病生存率（P=0.0496）、无局部复发生存率（P=0.065）和无远处转移生存率（P=0.017）。高表达GDF15的患者中,临床无颈部淋巴结转移、接受TPF诱导化疗者预后较好,总生存率（P=0.018）、无病生存率（P=0.010）、无局部复发生存率（P=0.042）和无远处转移生存率（P=0.006）显著为高。结论:GDF15表达可作为局部晚期口腔鳞癌的预后生物标志物,也可作为从TPF诱导化疗生存获益的预测性生物标志物。

关键词: 生长分化因子15, 口腔鳞癌, 诱导化疗, 预后性生物标志物, 预测性生物标志物

Abstract: PURPOSE: To figure out the prognostic value of GDF15 expression in patients with locally advanced oral squamous cell carcinoma (OSCC), and to explore the clinical usefulness of GDF15 as a potential predictive biomarker for TPF (docetaxel, cisplatin and 5-fluorouracil) induction chemotherapy. METHODS: Two hundred and fifty-six patients with locally advanced OSCC from a prospective, randomized trial were enrolled into this study. Immunohistochemical staining against GDF15 was used in the biopsy specimens from these patients. Prognostic analysis was performed in these patients, especially on the relationship between GDF15 expression and TPF induction chemotherapy. SPSS18.0 software package was used for statistical analysis. RESULTS: Among the 230 patients with biopsy specimens, lower GDF15 expression was detected in 68 patients and higher GDF15 expression in 162 patients. The patients with lower GDF15 expression had a better survival than those with higher GDF15 expression, including overall survival(P=0.046), disease-free survival(P=0.0496), locoregional recurrence-free survival(P=0.065) and distant metastasis-free survival(P=0.017). Furthermore, the cN- patients with higher GDF15 expression could benefit from TPF induction chemotherapy, including overall survival(P=0.018), disease-free survival (P=0.010), locoregional recurrence-free survival (P=0.042) and distant metastasis-free survival(P=0.006). CONCLUSIONS: GDF15 expression could be used as a prognostic biomarker for patients with locally advanced OSCC. cN- patients with higher GDF15 expression could benefit from TPF induction chemotherapy.

Key words: Growth differentiation factor 15, GDF 15, Oral squamous cell carcinoma, Induction chemotherapy, Prognostic biomarker, Predictive biomarker

中图分类号:

R739.8

唐晓, 孙文文, 朱东旺, 马捷, 马海龙, 刘莹, 谈亦然, 涂瑶瑶, 王丽珍, 李江, 钟来平, 张陈平, 张志愿. GDF15作为T3/T4cN0M0口腔鳞癌患者TPF诱导化疗预测性生物标志物的探讨[J]. 中国口腔颌面外科杂志, 2016, 14(2): 117-122.

TANG Xiao, SUN Wen-wen, ZHU Dong-wang, MA Jie, MA Hai-long, LIU Ying, TAN Yi-ran, TU Yao-yao, WANG Li-zhen, LI Jiang, ZHONG Lai-ping, ZHANG Chen-ping, ZHNAG Zhi-yuan. GDF15 can be used as a potential predictive biomarker for TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2016, 14(2): 117-122.

参考文献

[1] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer[J]. Nat Rev Cancer, 2011, 11(1): 9-22.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2014, 12(10): 1454-1487.
[4] Benasso M. Induction chemotherapy for squamous cell head and neck cancer: a neverending story?[J]. Oral Oncol, 2013, 49(8): 747-752.
[5] Zhong LP, Zhang CP, Ren GX, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma [J]. J Clin Oncol, 2013, 31(6): 744-751.
[6] Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1 [J]. Cytokine Growth Factor Rev, 2013, 24(4): 373-384.
[7] Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer [J]. J Cell Physiol, 2010, 224(3): 626-635.
[8] Khaled YS, Elkord E, Ammori BJ. Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer [J]. Cancer Biomark, 2012, 11(5): 183-190.
[9] Brown DA, Lindmark F, Stattin P, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer [J]. Clin Cancer Res, 2009, 15(21): 6658-6664.
[10] Wallin U, Glimelius B, Jirström K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer [J]. Br J Cancer, 2011, 104(10): 1619-1627.
[11] Staff AC, Bock AJ, Becker C, et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer [J]. Gynecol Oncol, 2010, 118(3): 237-243.
[12] Staff AC, Trovik J, Eriksson AG, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer [J]. Clin Cancer Res, 2011, 17(14): 4825-4833.
[13] Bock AJ, Stavnes HT, Kempf T, et al. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions [J]. Int J Gynecol Cancer, 2010, 20(9): 1448-1455.
[14] Zhao L, Lee BY, Brown DA, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling [J]. Cancer Res, 2009, 69(19): 7696-7703.
[15] Zhang L, Yang X, Pan HY, et al. Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma [J]. Oral Oncol,2009,45(7): 627-632.